-+ 0.00%
-+ 0.00%
-+ 0.00%

Clear Street Maintains Buy on Structure Therapeutics, Raises Price Target to $99

Benzinga·12/09/2025 12:22:40
Listen to the news
Clear Street analyst Kaveri Pohlman maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and raises the price target from $61 to $99.